SAN DIEGO, Jan. 25, 2021 /PRNewswire-PRWeb/ -- January Therapeutics, an oncology-focused biopharmaceutical research and development company, today announced the appointment of Steven Rosen, MD as Chief Medical Advisor. Dr. Rosen will support key aspects of clinical development for January's JNTX-101 program (Pro-drug albumin-encapsulated version of Gemcitabine – a backbone for many cancer treatments) and JNTX-104 (Pro-drug albumin-encapsulated version of 8-Chloro-Adenosine – a drug that has been used in patients with AML). Dr. Rosen will also lead January's patient advocacy program.
Dr. Rosen is the Provost and Chief Scientific Officer of the City of Hope National Medical Center. In that role he leads the Beckman Research Institute and the Irell & Manella Graduate School of Biological Sciences. Dr. Rosen received both his BS and MD from Northwestern University where he also completed his residency. He has authored over 450 publications in the field of Oncology and serves on a number of oncology foundation boards including AACR, ASCO, and the Leukemia & Lymphoma Society.
"We are very pleased to welcome Dr. Steve Rosen to January" said Sam Ellis, CEO of January Therapeutics. "His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to January."
About January Therapeutics
January Therapeutics is a biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of protein-based nanoparticle formulation. Their initial development programs are oncology focused, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors.
To learn more, visit https://januarytx.com
Investors should contact:
Sam Ellis, CEO
Sam Ellis, January Therapeutics, +1 858-245-7184, [email protected]
SOURCE January Therapeutics